ABSTRACT
Objective:To explore the clinical efficacy and influence on quality of life of Compound Kunshen Injection combined with SOX regimen (Tigio + Oxaliplatin) in the treatment of elderly patients with advanced gastric cancer.Methods:A total of 76 elderly patients with advanced gastric cancer admitted to Caidian District People's Hospital of Wuhan from May 2017 to December 2021 were retrospectively analyzed. Patients were divided into study group ( n=38) and control group ( n=38) according to different treatment methods. The study group was treated with Compound Kunshen Injection combined with SOX regimen, and the control group was treated with SOX regimen. All patients received at least 2 cycles of chemotherapy. The disease control rate (DCR) , the changes of serum carcinoembryonic antigen (CEA) and carbohydrate antigen 199 (CA199) before and after treatment of the two groups were compared. The occurrence of adverse reactions to chemotherapy and the improvement of quality of life related indicators before and after treatment were observed in the two groups. Results:The DCR of the study group was 84.2% (32/38) and that of the control group was 63.2% (24/38) , with a statistically significant difference ( χ2=4.34, P=0.037) . After treatment, CEA levels in both study group and control group were decreased compared with those before treatment [7.92 (5.00, 50.23) ng/ml vs. 40.08 (6.37, 68.18) ng/ml, Z=3.53, P<0.001; 40.24 (20.12, 53.69) ng/ml vs. 41.32 (11.50, 63.90) ng/ml, Z=2.06, P=0.044], and CEA level in the study group was decreased more significantly than that in the control group ( Z=1.99, P=0.048) . After treatment, CA199 levels in both study group and control group were decreased compared with those before treatment [20.23 (17.34, 71.31) U/ml vs. 70.14 (12.75, 96.95) U/ml, Z=2.70, P=0.007; 54.25 (30.54, 76.75) U/ml vs. 62.28 (23.00, 84.80) U/ml, Z=2.37, P=0.018], with no statistically significant difference in the reduction level of CA199 between the two groups ( Z=0.73, P=0.463) . Most of the adverse reactions in the two groups during chemotherapy were grade 1-2, which disappeared after symptomatic treatment. Compared with the control group, the study group had lower incidence of gastrointestinal reaction [26.3% (10/38) vs. 52.6% (20/38) , χ2=5.50, P=0.019], myelosuppression [18.4% (7/38) vs. 44.7% (17/38) , χ2=6.09, P=0.014] and peripheral neurotoxicity [21.1% (8/38) vs. 44.7% (17/38) , χ2=4.83, P=0.028]. The improvements of QOL score [78.9% (30/38) vs. 55.3% (21/38) , χ2=4.83, P=0.028], Karnofsky performance status score [71.1% (27/38) vs. 47.4% (18/38) , χ2=4.41, P=0.036], hemoglobin [73.7% (28/38) vs. 50.0% (19/38) , χ2=4.52, P=0.034] and pain control [65.8% (25/38) vs. 24.1% (16/38) , χ2=4.29, P=0.038] of the study group were better than those of the control group, with statistically significant differences. Conclusion:Compound Kunshen Injection combined with SOX regimen in the treatment of elderly patients with advanced gastric cancer can not only improve the DCR of patients, but also reduce the serum levels of tumor markers CEA and CA199, among which the CEA decline is more obvious, reduce the incidence of adverse reactions of chemotherapy and improve the quality of life of patients.
ABSTRACT
AIM: To explore the mechanism of action of alkaloid components of compound kushen Injection (CKI) in the treatment of lung cancer based on serum metabolomics, network pharmacology, and molecular docking techniques. METHODS: A lung cancer model was established in C57 mice by inoculation of Lewis mouse lung cancer tumor strain. Thirty male mice were randomly divided into normal group, model group and CKI group. The drug was administered by tail vein injection once daily for 17 consecutive days. Mouse serum was examined by ultrahigh performance liquid chromatography tandem mass spectrometry (LC-MS) metabolomics, and several multivariate statistical analyses including principal component analysis (PCA) and orthogonal partial least squares discriminant analysis (OPLS-DA), combined with databases such as the human metabolic database (HMDB) and related literature to identify and identify differential metabolites, the relevant metabolic pathways were searched for by the metaboanalyst online tool. Using network pharmacology, construct the“component-target-disease”network of CKI in the treatment of lung cancer. Molecular docking method was used to verify the interaction between potential active ingredients and core targets. Serum metabolomics was jointly analyzed with network pharmacology to construct a“metabolite-germinal-enzyme-gene” network. RESULTS: Through metabolomics technology, 16 differential metabolites associated with lung cancer were screened from serum, and CKI addback these differential metabolite levels compared with the model group. Metabolic pathways mainly involve retinol metabolism, tryptophan metabolism, glycerophospholipid metabolism and other metabolic pathways. Network pharmacology analysis indicated that CKI treatment of lung cancer mainly targets STAT3, MAPK3, and MAPK1, which are closely related to proteoglycans, cellular senescence, and HIF − 1 signaling pathways in cancer. CONCLUSION: This article explains the mechanism of CKI in treating lung cancer from the perspective of metabonomics and network pharmacology, and provides basis for further study of CKI.
ABSTRACT
Bladder cancer is the most common malignancy of the urinary system. Compound Kushen Injection (CKI) is a Chinese medicinal preparation that has been widely used in the treatment of various types of cancers in the past two decades. However, the pharmacological effect of CKI on bladder cancer is not still completely understood. In the current study, network pharmacology combined with bioinformatics was used to elucidate the therapeutic mechanism and potential targets of CKI in bladder cancer. The mechanism by which CKI was effective against bladder cancer was further verified in vitro using human bladder cancer cell line T24. Network pharmacology analysis identified 35 active compounds and 268 target genes of CKI. Bioinformatics data indicated 5500 differentially expressed genes associated with bladder cancer. Common genes of CKI and bladder cancer suggested that CKI exerted anti-bladder cancer effects by regulating genes such as MMP-9, JUN, EGFR, and ERK1. Functional enrichment analysis indicated that CKI exerted therapeutic effects on bladder cancer by regulating certain biological processes, including cell proliferation, cell migration, and cell apoptosis. In addition, Kyoto Encyclopedia of Genes and Genomes enrichment analysis implicated pathways related to cancer, bladder cancer, and the PI3K-Akt signaling pathway. Consistently, cell experiments indicated that CKI inhibited the proliferation and migration of T24 cells, and induced their apoptosis. Moreover, RT-qPCR and Western blot results demonstrated that CKI was likely to treat bladder cancer by down-regulating the gene and protein expression of MMP-9, JUN, EGFR, and ERK1. CKI inhibited the proliferation and migration, and induced the apoptosis of T24 bladder cancer cells through multiple biological pathways and targets. CKI also exhibited significant effects on the regulation of key genes and proteins associated with bladder cancer. Overall, our findings provide solid evidence and deepen current understanding of the therapeutic effects of CKI for bladder cancer, and further support its clinical use.
Subject(s)
Humans , Computational Biology , Drugs, Chinese Herbal , Network Pharmacology , Phosphatidylinositol 3-Kinases , Urinary Bladder Neoplasms/geneticsABSTRACT
OBJECTIVE Compound Kushen injection (CKI) is a bis-herbal formulation extracted from Kushen (Radix Sophorae Flavescentis) and Baituling (Rhizoma Heterosmilacis Japonicae). Clinically, it is used as the adjuvant treat?ment of cancer. However, with the increased application, the cases of immediate hypersensitivity reactions (IHRs) also gradually rise. In this study, we investigated the underlying mechanism(s) and active constituent(s) for CKI-induced IHRs in experimental models. METHODS T helper 2 (Th2) immunity-amplified mice were prepared by aluminum adjuvant. Anaphylactic shock was detected by measuring rectal thermometry in propranolol pretreated mice. For evaluating micro?vascular permeability, Evans blue extravasation assay was used. Platelet-activating factor (PAF), serum total IgE (tIgE) and mouse mast cell protease 1 (MMCP1) were measured by ELISA. RESULTS The obtained results showed that CKI did not elevate serum tIgE and MMCP1 after consecutive immunization for five weeks, but could induce Evans blue extravasation (local) and cause obvious hypothermia (systemic) after a single injection. Further study showed that alka?loids in Kushen, especially matrine, were responsible for CKI-induced IHRs. Mechanism study showed that various PAF receptor antagonists could significantly counter CKI-induced IHRs locally or systemically. In cell system, CKI was able to promote PAF production in a non-cell-selective manner. In cell lysate, the effect of CKI on PAF production became stron?ger and could be abolished by blocking de novo pathway. CONCLUSION In conclusion, our study identifies, for the first time, that CKI is a PAF inducer. It causes non-immunologic IHRs, rather than IgE-dependent IHRs, by promoting PAF production through de novo pathway. Alkaloids in Kushen, especially matrine, are the prime culprits for IHRs. Our find?ings may provide a potential approach for preventing and treating CKI-induced IHRs.
ABSTRACT
OBJECTIVE: To establish a high-performance liquid gel chromatography (HPLC-ELSD) method for the detection of macromolecular substances in Compound Kushen injection. METHODS: TSKgel G2000SWXL (7.8 mm×300 mm, 5 μm) chromatographic column was used. A 20 mmol•L-1 ammonium acetate aqueous solution was used as the mobile phase. The column temperature was maintained at 25℃, the flow rate was 0.8 mL•min-1, and the parameters of the evaporative light detector (drift tube temperature 55℃, atomization temperature 55℃, nitrogen flow rate, 1.8 L•min-1), a method for detecting macromolecular substances was established, and eleven batches of Compound Kushen injection were tested for macromolecular substances. RESULTS: No macromolecular substances was detected in the eleven batches of Compound Kushen injection, indicating that after the step-by-step removal of impurities, macromolecular substances have been removed from the finished Compound Kushen injection products. CONCLUSION: This method is simple and fast, which can be used for the detection of macromolecular substances in Compound Kushen injection, it provides a basis for improving the quality standards of Compound Kushen injection.
ABSTRACT
Objective: To investigate the effect of Compound Kushen Injection on proliferation, apoptosis, and autophagy of bladder cancer T24 cells, and to explore the molecular mechanisms involved, and provide theoretical basis for Compound Kushen Injection in clinical treatment of bladder cancer. Methods: The effect of Compound Kushen Injection on proliferation of bladder cancer cells was detected by CCK-8 method. Flow cytometry was used to detect the effect of Compound Kushen Injection on bladder cancer cell apoptosis. MDC staining was used to detect the effect of Compound Kushen Injection on autophagy of bladder cancer cells. Western blotting and immunofluorescence experiments were used to detect the effect of Compound Kushen Injection on key protein involved in apoptosis and autophagy of bladder cancer cells. Results: Compound Kushen Injection effectively inhibited the proliferation of bladder cancer T24 cells. Compound Kushen Injection induced bladder cancer cells to undergo apoptosis and autophagy. The results of Western blotting and immunofluorescence experiments showed that as the concentration of Compound Kushen Injection increased, the expressions of Bcl-2 and P62 in bladder cancer T24 cells were gradually decreased, and the expressions of Bax, cleaved-Caspase 3, Beclin1, and LC3Ⅱ were increased (P < 0.05), but Bcl-2/Bax ratio was decreased (P < 0.05). Conclusion: Compound Kushen Injection can inhibit the proliferation of bladder cancer T24 cells, regulate autophagy of bladder cancer T24 cells, and induce bladder cancer T24 cell apoptosis. Key words:
ABSTRACT
Objective::To observe the effect of compound Kushen injection on the expressions of transforming growth factor-β1 (TGF-β1), drosophila mothers against decapentaplegic protein 3 (Smad3), glycogen synthase kinase-3β (GSK-3β) and β-catenin mice models with radiation-induced pulmonary injury (RIPI), in order to explore its possible mechanism of action. Method::On XStrahl precision radiation research platform for small animals (SARRP), a single 20 Gy bilateral lung field irradiation was performed to establish a mice model of RIPI. Thirty-two mice were randomly divided into normal control group, model group, compound Kushen injection group and dexamethasone injection group. The normal control group and the model group were given an equal volume of 0.9%sodium chloride solution and injected intraperitoneally for 4 weeks. The pathology of lung tissue tissues was observed by using hematoxylin-eosin (HE) staining. Immunohistochemical(IHC) was used to detect the expressions of E-cadheren and Vimentin proteins in mice lung tissues.Real-time polymerase chain reaction (Real-time PCR) was used to detect the mRNA expressions of TGF-β1, Smad3, GSK-3β and β-cateninin.Western blot was used to detect the protein expressions of TGF-β1, Smad3, GSK-3β and β-cateninin. Result::Compared with the normal group, the pulmonary coefficient of the model group was significantly decreased (P<0.01). Inflammatory cell infiltration, pulmonary interstitial edema, congestion, destruction of alveolar structure and partial alveolar atrophy were observed in the lung tissues of the model group. Compared with the model group, in the compound Kushen injection group, the levels of infiltration of lung inflammatory cells and pulmonary interstitial lesions in mice, the expression of Vimentin in lung tissues (P<0.01), and the expressions of TGF-β1, Smad3, GSK-3β and β-cateninin were significantly decreased (P<0.01), whereas the expression of E-cadheren was significantly increased (P<0.01). However, compared with the dexamethasone injection group, in the compound Kushen injection group, the pathological changes of lung tissues were similar, and the expression levels of E-cadheren, Vimentin, TGF-β1, Smad3, GSK-3β and β-cateninin were not significantly different. Conclusion::Compound Kushen injection can alleviate pulmonary fibrosis of lung in the treatment of RIPI, and the mechanism may be associated with inhibiting the mRNA and protein expressions of TGF-β1, Smad3, GSK-3β and β-catenin related to epithelial-mesenchymal transition(EMT), promoting the expression of E-cadheren, and inhibiting the expression of Vimentin, so as to inhibit the occurrence of EMT.
ABSTRACT
OBJECTIVE To explore the inhibition of Compound Kushen Injection (CKI) on the prolif-eration, in vitro migration and in vitro invasion of SMMC-7221 cells and the mechanism. METHODS SMMC-7221 cells were treated with CKI of different dilution percentages (0.0% (cell control), 2.5%, 5.0% and 10.0%) for 24 h. The viability of SMMC-7221 cells was evaluated by MTT assay, while the ability of cell migration and invasion was evaluated by the wound healing and transwell chamber assay, respectively. Cells were treated with 0.0%, 5.0% and 10.0% CKI for 12 or 24 h, before the mRNA and protein levels of NF-kB were detected by RT-PCR and Western blotting, respectively. RESULTS Compared with the cell control group, the survival rates in 2.5%, 5.0% and 10.0% CKI groups were reduced to (92±7)%, (77±5)% (P<0.01) and (56±7)% (P<0.01), the migration rates to (90±7)%, (50±10)% (P<0.01) and (25±5)% (P<0.01), and the invasion rates to (98±7)%, (51 ±10)% (P<0.01) and (20±5)% (P<0.01), respectively. The NF-kB mRNA levels in 5.0% and 10.0% CKI groups were reduced to (42±9)% and (46±10)% of the cell control group (P<0.01) after 12 h treatment of CKI, and the protein levels of NF-kB were reduced to (67±16)% and (27±11)% of cell control group after 24 h treatment with CKI, respectively (P<0.01). CONCLUSION CKI can inhibit the proliferation, migration and invasion of SMMC-7221 cells in vitro, and the mechanism may be related to the inhibition of NF-kB signal pathway.
ABSTRACT
Objective The adverse drug reaction (ADR) reports of compound Kushen injection in Qingdao Central Hospital were analyzed to improve the level of safe and rational use of drugs.Methods We investigated 35 cases of severe ADR reports induced by compound Kushen injection in Qingdao Central Hospital from 2016.09 to 2018.03 retrospectively.Then the type of report,relevance evaluation and prognosis,ADR occurrence and recovered time,involved system/organs and main clinical manifestations were analyzed.Results The new moderate and new severe ADR incident were 51.4％ of 35 ADR reports.Twenty-nine cases of the ADR were occurred 30 minutes after injection.Twenty-three cases of ADR clinical symptoms can be recovered after 30 minutes.The main ADR was the digestive system reaction,followed by the neural system,respiratory system and cardiovascular system.Conclusions It is important to pay attention to the occurrence of compound Kushen injection ADR and strengthen its monitoring.
ABSTRACT
Objective To evaluate the efficacy and safety of compound Kushen injection as an adjuvant for chemotherapy in treatment of advanced digestive tract cancer. Methods A prospective, randomized, parallel controlled, single center clinical trial was conducted. One hundred and forty-four patients with advanced gastrointestinal cancer admitted to the Department of Oncology of Fangta Traditional Chinese Medicine (TCM) Hospital of Songjiang District in Shanghai from July 2014 to December 2016 were enrolled, and they were divided into a control group and an observation group, 72 cases in each group. The patients in control group received routine chemotherapy, and on the basis of routine chemotherapy, the patients in the observation group was given compound Kushen injection 20 mL having diluted with 250 mL sodium chloride for intravenous drip, once a day for 14 days constituting 1 therapeutic course. After consecutive 2 therapeutic courses, the clinical efficacy was observed, the differences in disease control rate (DCR), Karnofsky score (KPS), TCM syndrome curative effect and adverse reactions were compared between the two groups, follow-up was carried out for 7-24 months, survival rate and progression free survival (PFS) time was observed in the two groups. Results After treatment, the DCR, KPS score, total effective rate of TCM syndrome in the observation group were significantly higher than those of control group [DCR: 59.7% (43/72) vs. 43.1% (31/72), KPS score: 70.9±6.2 vs. 64.8±4.8, total curative effect of TCM syndrome: 63.89% (46/72) vs. 41.67% (30/72), all P < 0.05], and the adverse effect rate was significantly lower than that of control group [25.0% (18/72) vs. 41.7% (30/72), P < 0.05]. In the end of follow-up, there were 12 survival cases in the control group, and 22 survival cases in observation group, and survival rate and the PFS time in observation group were significantly longer than those in the control group [survival rate: 30.6% vs. 16.7%; PFS time (months): 15.3±4.0 vs. 13.2±4.2, P < 0.05]. Conclusions The therapeutic effect of using Kushen injection as an adjuvant for chemotherapy in treatment of patients with advanced digestive tract cancer is relatively good, can improve the life quality of patients, and lower the incidence of adverse reactions.
ABSTRACT
This study was aimed to analyze the clinical characteristics of Compound Kushen Injection in the treatment of patients with malignant lymphoma in the real world based on the electronic medical record,and to provide a reference for its rational application.The electronic medical data of 3 674 patients with malignant lymphoma using Compound Kushen Injection was extracted.General information,diagnostic information,and medication information were analyzed on the basis of frequency and rate of descriptive analysis.The results showed that the average age of patients was 54.95 yearsold,with more males than females.Patients were mainly from the department of oncology and hematology.Based on hospital outcomes in hospitalized patients,the clinical total effective rate was 66.15％.The single medication dosage was mostly 10-20 ml.The course of treatment was mainly 4-14 days.The common western medications in combination included dexamethasone,tropisetron injection,metoclopramide tablet,thymopolypeptides injection,cyclophosphamide injection,and etc.Common pharmacological effects of combined western medicine included anti-tumor chemotherapy drugs,immunomodulatory drugs,glucocorticoid drugs,antibiotic drugs and so on.It was concluded that the clinical dosage,scope of malignant lymphoma treatment using Compound Kushen Injection in the real world were consistent with the specification.And characteristics of the crowd using Compound Kushen injection is clear and in line with the general rule of malignant lymphoma and clinical positioning of varieties.Based on the hospital outcomes,the clinical efficacy is determined to have precise effect on hospitalized patients.The drug combination type is extensive.
ABSTRACT
Objective To evaluate the efficacy and safety of compound Kushen injection as an adjuvant for chemotherapy in treatment of advanced digestive tract cancer. Methods A prospective, randomized, parallel controlled, single center clinical trial was conducted. One hundred and forty-four patients with advanced gastrointestinal cancer admitted to the Department of Oncology of Fangta Traditional Chinese Medicine (TCM) Hospital of Songjiang District in Shanghai from July 2014 to December 2016 were enrolled, and they were divided into a control group and an observation group, 72 cases in each group. The patients in control group received routine chemotherapy, and on the basis of routine chemotherapy, the patients in the observation group was given compound Kushen injection 20 mL having diluted with 250 mL sodium chloride for intravenous drip, once a day for 14 days constituting 1 therapeutic course. After consecutive 2 therapeutic courses, the clinical efficacy was observed, the differences in disease control rate (DCR), Karnofsky score (KPS), TCM syndrome curative effect and adverse reactions were compared between the two groups, follow-up was carried out for 7-24 months, survival rate and progression free survival (PFS) time was observed in the two groups. Results After treatment, the DCR, KPS score, total effective rate of TCM syndrome in the observation group were significantly higher than those of control group [DCR: 59.7% (43/72) vs. 43.1% (31/72), KPS score: 70.9±6.2 vs. 64.8±4.8, total curative effect of TCM syndrome: 63.89% (46/72) vs. 41.67% (30/72), all P < 0.05], and the adverse effect rate was significantly lower than that of control group [25.0% (18/72) vs. 41.7% (30/72), P < 0.05]. In the end of follow-up, there were 12 survival cases in the control group, and 22 survival cases in observation group, and survival rate and the PFS time in observation group were significantly longer than those in the control group [survival rate: 30.6% vs. 16.7%; PFS time (months): 15.3±4.0 vs. 13.2±4.2, P < 0.05]. Conclusions The therapeutic effect of using Kushen injection as an adjuvant for chemotherapy in treatment of patients with advanced digestive tract cancer is relatively good, can improve the life quality of patients, and lower the incidence of adverse reactions.
ABSTRACT
Objective To analyze the effect of cluster nutrition intervention and psychological intervention combined with compound Kushen injection on postoperative patients with esophageal cancer. Methods 80 patients with esophageal cancer who underwent postoperative radiotherapy and chemotherapy were divided into two groups. The control group was treated with chemotherapy alone. The observation group was treated with compound bitter ginseng injection and cluster nutrition intervention. Psychological intervention therapy. The total effective rate, the nutritional index before and after treatment, the SF-36 quality of life score and the complication rate were compared. Results The total effective rate and the post-treatment nutritional value of the observation group were higher than those of the control group. After treatment, the SF-36 scale was higher than the control group, the incidence of adverse reactions was lower than that of the control group(P<0.05). Conclusion The combination of intensive nutrition, psychological intervention and compound Sophora flavescens injection can improve the nutritional status, improve the curative effect, reduce the adverse reaction and improve the quality of life of patients with esophageal cancer after radiotherapy and chemotherapy.
ABSTRACT
Objective:To study the stability of compound Kushen mixed liquid to provide reliable evidence for safe clinical drug application.Methods:Compound Kushen injection was mixed respectively with 0.9% sodium chloride injection and 5% glucose injection,and then placed under the different conditions for 0,1,2,4,8,12,24 and 48 h.HPLC was conducted to determine the content changes of four components in compound Kushen mixed liquid,and the appearance,pH and insoluble particles were observed as well.Results:The mixed liquid of compound Kushen with 0.9% sodium chloride injection was stable in 48 h without the influence of light and temperature.However,the mixed liquid of compound Kushen with 5% glucose injection had poorer stability with storage time shorter than 12 h at room temperature and 2 h at high temperature.Conclusion:The stability of the mixed liquid of compound Kushen is closely related to the pH value of solvent.0.9% Sodium chloride injection is recommended as the solvent,and the mixed liquid should be used up in 48 h.
ABSTRACT
Objective To explore the effect of compound sophora flavescens injection on intraperitoneal chemotherapy of cisplatin in malignant ascites of gastric cancer patients and its influence on immune function.Methods 90 cases with malignant ascites of gastric cancer failures were researched,who from May 2014 to May 2016.According to random number table, they were divided into observation group and control group, 45 cases in each group.The control group was treated with intraperitoneal chemotherapy of cisplatin alone, and the treatment group was treated by intraperitoneal chemotherapy with compound Kushen injection combined with cisplatin.The two groups of patients before and after treatment, compared the level of immune function indicators, while observing the two groups of patients after treatment, short-term efficacy, quality of life improvement and adverse reactions.Results Observation group of patients with efficient and control rates were higher than the control group patients, but no obvious difference between groups.The stability factor of 55.55%of patients with observation group was obviously higher than that of control group 22.22%of the patients, the clear difference between groups (P<0.05).Before the treatment, two groups of patients of CD3 +, CD4 +, CD8 +and CD4 +/CD8 +T cell subsets and NK cells was no significant difference.After treatment, two groups of patients of CD3 +, CD4 +, CD4 +/CD8 + T cell subsets and NK cells were significantly increased than before treatment ( P<0.05 ) , and CD8 + than before treatment significantly reduced ( P <0.05 ) , while the observation group of CD3 +, CD4 +, CD4 +/CD8 +T cell subsets and NK cells was significantly higher than that of control group ( P <0.05 ) , and CD8 + was significantly lower than control group (P <0.05).The control group in the improvement of quality of life of patients with effective rate of 35.55%compared with 80.00% of the observation group of patients, significantly lower, more obvious differences between groups (P <0.05).Observation group of patients the incidence of gastrointestinal reaction and liver function abnormalities were 0.00%, 8.88%, significantly lower than the control group patients were 11.11%, 22.22%, there exists significant difference between groups (P <0.05).Fatigue, nausea, vomiting and 2 groups of patients compared the incidence rate of no significant difference.Conclusion The combined use of compound Kushen injection combined with cisplatin intraperitoneal perfusion chemotherapy in patients with malignant ascites of gastric cancer for treatment,effect is remarkable,Can effectively improve the patient's T cell subsets and NK cells,Improve the patient's immune function.
ABSTRACT
Objective To observe the clinical efficacy and safety of compound Kushen Injection in the patients with malignant ascites. Methods Totally 139 patients with malignant ascites were randomly divided into treatment group and control group. 30 mL compound Kushen Injection was given to the treatment group, and 100 mg cisplatin was given to the control group through peritoneal perfusion once a week, for 3 weeks. The changes of urine volume, abdominal perimeter, blood-Rt, function of liver and kidney, and gastrointestinal reaction were detected before and after treatment, with a purpose to evaluate the total efficacy and safety. Results The total effective rate was 80.56% (58/72) in treatment group, and 86.57% (58/67) in the control group, without significant difference between the two groups. The incidences of bone marrow suppression, liver and kidney damage, and nausea and vomiting of gastrointestinal reaction were lower in the treatment group than the control group. Conclusion The effects of compound Kushen Injection and cisplatin have equal efficacy for the treatment of malignant ascites, but the former was superior to the latter on safety.
ABSTRACT
Objective To investigate the prevention and treatment effects of Compound Kushen Injection on acute radiation esophagitis. Methods Eighty-two eligible patients with esophageal cancer were randomly divided into the treatment group (41 cases) and the control group (41 cases). All the patients received radiotherapy. Throughout the course of radiotherapy, patients in the treatment group received Compound Kushen Injection, and patients in the control group received Kangfuxin Liquid. Occurrence time and level of radiation esophagitis, and dosage of painkillers were observed. Results Different degrees of acute esophageal toxicity were observed in the two groups. The occurrence rate of high level (degree III and degree IV) acute radiation esophagitis was 7.3%(3/41) in the treatment group, and 31.7%(13/41) in the control group. There was significant difference between the two groups (P<0.05). The dosage of the analgesic drug (Fentanyl Transdermal System) in the treatment group was far less than the controlled group (P<0.001). Conclusion Compound Kushen Injection could decrease the incidence rate of acute radiation esophagitis, and reduce the high-level esophagitis and the dosage of the analgesic drug, which can help the completion of radiation.
ABSTRACT
OBJECTIVE: To develop an on-line analysis method based on near infrared spectroscopy (NIRS) for monitoring the percolation process of compound Kushen injection traditional Chinese medicines. METHODS: Samples and correlative spectra were collected with online equipment in percolation process. The contents of total alkaloids and total solids measured with standard methods were used as reference values. Multivariate calibration models based on partial least squares (PLS) algorithm were developed to correlate the spectra and the reference values. RESULTS: The correlation coefficients of the calibration models for total alkaloids and total solids were 0.9979 and 0.9960 with root mean square errors (RMSECs) of 0.0721 g · L-1 and 0.0811%, respectively. External validation samples collected on-line were used to evaluate the quantitative models. The correlation coefficients between the predicted value and the reference value were 0.9915 and 0.9990 with root mean square errors of prediction (RMSEPs) of 0.1950 g· L-1 and 0.0681%, respectively. CONCLUSION: The presented method is rapid, accurate and reliable, which can be used for monitoring the percolation process of compound Kushen injection.
ABSTRACT
OBJECTIVE:To analysis the therapeutic effect of Compound kushen injection as adjunctive treatment for breast cancer.METHODS:67 breast cancer patients in our department from Jan.1st,2007 to Jan.1st,2009 were randomly divided into treatment group(n=35) and control group(n=32).Treatment group received standard chemotherapy with Compound kushen injection as adjunctive therapy and control group received standard chemotherapy only after modified radical mastectomy.RESULTS:The toxicity adverse reaction of treatment group were decreased significantly as compared with control group(P
ABSTRACT
OBJECTIVE:To investigate the infusion solutions which are compatible with Compound kushen injection. METHODS:The insoluble particles of kushen injection in four kinds of infusion solutions were detected respectively by light blockage method.RESULTS:Insoluble particles of different size and number were noted for Compound kushen injection when mixed respectively with four kinds of infusion solutions,but the insoluble particles in all kinds of infusion solutions except 10% glucose injection were all within the range specified in China Pharmacopeia(2005 edition).CONCLUSION: 0.9% sodium ch-loride injection is the optimal compatible infusion solution for Compound kushen injection.